prazosin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	4209	19216-56-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prazosin prazosin hydrochloride furazosin prazosin HCl	A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Molecular weight: 383.41 Formula: C19H21N5O4 CLOGP: 2.03 LIPINSKI: 0 HAC: 9 HDO: 1 TPSA: 106.95 ALOGS: -2.74 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1.40 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.49 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	68 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.73 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 23, 1976	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Atrioventricular block first degree	113.91	16.68	37	4791	6149	46675085
Unmasking of previously unidentified disease	48.90	16.68	12	4816	719	46680515
Sinus bradycardia	45.25	16.68	24	4804	13758	46667476
Circulatory collapse	45.07	16.68	28	4800	21596	46659638
Electrocardiogram ST segment elevation	40.46	16.68	15	4813	3680	46677554
Posterior reversible encephalopathy syndrome	40.42	16.68	23	4805	15118	46666116
Norepinephrine increased	40.20	16.68	7	4821	73	46681161
Electrocardiogram repolarisation abnormality	37.89	16.68	11	4817	1254	46679980
Systolic dysfunction	37.48	16.68	11	4817	1303	46679931
Ventricular hypokinesia	32.01	16.68	13	4815	4065	46677169
Electrocardiogram QRS complex prolonged	31.56	16.68	14	4814	5435	46675799
Toxicity to various agents	31.17	16.68	68	4760	211698	46469536
Hypotension	27.98	16.68	69	4759	232520	46448714
Cardiac arrest	27.59	16.68	40	4788	90359	46590875
Hypertrichosis	27.39	16.68	8	4820	932	46680302
Cardiac hypertrophy	26.46	16.68	8	4820	1049	46680185
Cardiotoxicity	25.78	16.68	13	4815	6709	46674525
Overdose	25.31	16.68	41	4787	101938	46579296
Drug withdrawal syndrome	23.94	16.68	21	4807	27363	46653871
Metabolic acidosis	22.99	16.68	24	4804	38756	46642478
Bradycardia	22.69	16.68	31	4797	66267	46614967
Ventricular extrasystoles	22.22	16.68	14	4814	11049	46670185
Suicidal ideation	21.82	16.68	28	4800	56354	46624880
Cardio-respiratory arrest	20.49	16.68	28	4800	59841	46621393
Dissociative identity disorder	20.49	16.68	4	4824	81	46681153
Haemophagocytic lymphohistiocytosis	20.47	16.68	12	4816	8330	46672904
Hypertensive crisis	19.58	16.68	14	4814	13601	46667633
Status epilepticus	19.25	16.68	14	4814	13965	46667269
Electrocardiogram QRS complex shortened	19.25	16.68	5	4823	377	46680857
Electrocardiogram QT prolonged	19.09	16.68	25	4803	51300	46629934
Stress cardiomyopathy	18.58	16.68	11	4817	7773	46673461
Withdrawal syndrome	18.08	16.68	15	4813	18119	46663115
Acute kidney injury	17.63	16.68	59	4769	235796	46445438
Coma scale abnormal	17.23	16.68	9	4819	4997	46676237
Hypovolaemic shock	16.93	16.68	9	4819	5174	46676060

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Priapism	83.85	15.64	31	4924	4712	29942811
Parasomnia	76.81	15.64	16	4939	278	29947245
Antidepressant drug level above therapeutic	67.12	15.64	13	4942	153	29947370
Analgesic drug level above therapeutic	62.08	15.64	13	4942	232	29947291
Abnormal sleep-related event	47.50	15.64	12	4943	502	29947021
Serotonin syndrome	44.86	15.64	31	4924	17860	29929663
Suicidal behaviour	44.06	15.64	14	4941	1348	29946175
Vasoplegia syndrome	32.75	15.64	11	4944	1260	29946263
Drug interaction	31.60	15.64	88	4867	199480	29748043
Sudden cardiac death	30.26	15.64	14	4941	3738	29943785
Orthostatic hypotension	26.90	15.64	26	4929	23953	29923570
Somnambulism	25.94	15.64	12	4943	3202	29944321
Compartment syndrome	25.40	15.64	11	4944	2516	29945007
Sinus bradycardia	24.11	15.64	18	4937	11677	29935846
Spleen tuberculosis	24.01	15.64	4	4951	18	29947505
Syncope	20.38	15.64	44	4911	84859	29862664
Hyperlactacidaemia	18.79	15.64	9	4946	2597	29944926
Pulmonary congestion	17.03	15.64	15	4940	12272	29935251
Electrocardiogram QT prolonged	16.94	15.64	25	4930	35810	29911713
Aspiration	16.91	15.64	14	4941	10537	29936986
Suicidal ideation	16.80	15.64	25	4930	36089	29911434
Food interaction	16.50	15.64	6	4949	869	29946654
Overdose	16.15	15.64	40	4915	84297	29863226

Pharmacologic Action:

Source	Code	Description
ATC	C02CA01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Alpha-adrenoreceptor antagonists
ATC	C02LE01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Alpha-adrenoreceptor antagonists and diuretics
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
FDA EPC	N0000175553	alpha-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:35674	antihypertensive
CHEBI has role	CHEBI:37890	alpha-adrenoceptor antagonists
CHEBI has role	CHEBI:76779	prolyl oligopeptidase (ec 3.4.21.26) inhibitor

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Benign prostatic hyperplasia	off-label use	266569009
PTSD related nightmares	off-label use	428687006
Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares	off-label use
End stage renal disease	contraindication	46177005	DOID:784
Narcolepsy	contraindication	60380001	DOID:8986
Cataract surgery	contraindication	110473004
Micturition syncope	contraindication	234168001
Syncope	contraindication	271594007
Intraoperative floppy iris syndrome	contraindication	418801006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.22	Basic
pKa2	0.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	INVERSE AGONIST	Ki	10.40		CHEMBL	IUPHAR
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	INVERSE AGONIST	Ki	9.68		CHEMBL	IUPHAR
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	INVERSE AGONIST	Ki	9.70		CHEMBL	IUPHAR
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.73		WOMBAT-PK
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	5		CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.87		CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.68		CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.08		CHEMBL
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	9.48		CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.80		CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.89		CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.62		CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN		IC50	4.42		CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.80		CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		IC50	9.07		CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5		CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone]	Enzyme	P16083	NQO2_HUMAN		IC50	8.11		CHEMBL
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.58		DRUG MATRIX
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN		IC50	5.16		DRUG MATRIX
Interstitial collagenase	Enzyme	P03956	MMP1_HUMAN		IC50	5.39		DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_MESAU		Ki	9.08		CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2A_RAT 5HT2B_RAT 5HT2C_RAT		IC50	4.38		CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2A_RAT ADA2B_RAT ADA2C_RAT		Ki	9.40		CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_RAT		Ki	5.78		CHEMBL
Alpha-1D adrenergic receptor	GPCR		ADA1D_RAT		Ki	9.70		CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_PIG		Ki	5.39		CHEMBL
Alpha-2 adrenergic receptor	GPCR		ADA2A_MOUSE ADA2B_MOUSE ADA2C_MOUSE		Ki	7.89		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	5.82		CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1A_RAT ADA1B_RAT ADA1D_RAT		Kd	10.99		CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		Ki	9.77		CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_BOVIN		Ki	6.97		CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		Ki	10.15		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	5.63		CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	10		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		IC50	4.96		CHEMBL
Mu-type opioid receptor	GPCR		OPRM_RAT		Ki	9.70		CHEMBL
Beta-casein	Unclassified		CASB_RAT		Ki	9.44		CHEMBL

External reference:

ID	Source
4019901	VUID
N0000147986	NUI
D00609	KEGG_DRUG
19237-84-4	SECONDARY_CAS_RN
4018850	VANDF
4019901	VANDF
C0032912	UMLSCUI
CHEBI:8364	CHEBI
XRA	PDB_CHEM_ID
CHEMBL2	ChEMBL_ID
CHEMBL1558	ChEMBL_ID
D011224	MESH_DESCRIPTOR_UI
DB00457	DRUGBANK_ID
503	IUPHAR_LIGAND_ID
2593	INN_ID
XM03YJ541D	UNII
4893	PUBCHEM_CID
203210	RXNORM
2426	MMSL
5345	MMSL
d00138	MMSL
000635	NDDF
004491	NDDF
387283005	SNOMEDCT_US
387433003	SNOMEDCT_US
76058001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Minipress	HUMAN PRESCRIPTION DRUG LABEL	1	0069-4310	CAPSULE	1 mg	ORAL	NDA	22 sections
Minipress	HUMAN PRESCRIPTION DRUG LABEL	1	0069-4370	CAPSULE	2 mg	ORAL	NDA	22 sections
Minipress	HUMAN PRESCRIPTION DRUG LABEL	1	0069-4380	CAPSULE	5 mg	ORAL	NDA	22 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4067	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4068	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4069	CAPSULE	5 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1101	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2302	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3205	CAPSULE	5 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7020	CAPSULE	1 mg	ORAL	ANDA	20 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7021	CAPSULE	2 mg	ORAL	ANDA	20 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7022	CAPSULE	5 mg	ORAL	ANDA	20 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-666	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-667	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-668	CAPSULE	5 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-860	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-861	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-248	CAPSULE	5 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-260	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-035	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-868	CAPSULE	2 mg	ORAL	ANDA	22 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0379	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1948	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1948	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2845	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5512	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51079-630	CAPSULE	1 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51079-631	CAPSULE	2 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51079-632	CAPSULE	5 mg	ORAL	ANDA	21 sections
Prazosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53808-1075	CAPSULE	2 mg	ORAL	ANDA	21 sections